Cargando…

ExtaviJect® 30G device for subcutaneous self-injection of interferon beta-1b for multiple sclerosis: a prospective European study

BACKGROUND: The ExtaviJect® 30G autoinjector was developed to facilitate parenteral self-administration of interferon beta-1b (Extavia®), a first-line disease-modifying therapy in patients with multiple sclerosis. Our aim was to assess patient compliance with treatment when using the autoinjector, p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Boeru, Gabriel, Milanov, Ivan, De Robertis, Francesca, Kozubski, Wojciech, Lang, Michael, Rojas-Farreras, Sònia, Tomlinson, Mark
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2013
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3832381/ https://www.ncbi.nlm.nih.gov/pubmed/24255602 http://dx.doi.org/10.2147/MDER.S52590

Ejemplares similares

Autoinjectors for administration of interferon beta-1b in multiple sclerosis: patient preferences and the ExtaviPro™ 30G and Betacomfort(®) devices
por: Thakur, Kunal, et al.
Publicado: (2013)

A brand-new era has begun for JECT
por: Wong, Raymond K
Publicado: (2023)

Patient satisfaction with ExtaviPro™ 30G, a new auto-injector for administering interferon β-1b in multiple sclerosis: results from a real-world, observational EXCHANGE study
por: Hoffmann, Frank A., et al.
Publicado: (2017)

COMPARE: Pharmacokinetic profiles of subcutaneous peginterferon beta‐1a and subcutaneous interferon beta‐1a over 2 weeks in healthy subjects
por: Hu, Xiao, et al.
Publicado: (2016)

Subcutaneous interferon beta-1a in COVID-19: raking the ashes of an intervention trial
por: Wilkinson, Tom
Publicado: (2021)

Efficacy of subcutaneous interferon-beta in COVID-19: a meta-analysis and systematic review
por: Asif, Abuzar A., et al.
Publicado: (2021)

Pregnancy outcomes in interferon-beta-exposed patients with multiple sclerosis: results from the European Interferon-beta Pregnancy Registry
por: Hellwig, Kerstin, et al.
Publicado: (2020)

Exercise interveNtion outdoor proJect in the cOmmunitY for older people – the ENJOY Senior Exercise Park project translation research protocol
por: Levinger, Pazit, et al.
Publicado: (2019)

Exercise interveNtion outdoor proJect in the cOmmunitY for older people – results from the ENJOY Seniors Exercise Park project translation research in the community
por: Levinger, Pazit, et al.
Publicado: (2020)

Exercise interveNtion outdoor proJect in the cOmmunitY—ENJOY program for independence in dementia: a feasibility pilot randomised controlled trial study protocol
por: Levinger, Pazit, et al.
Publicado: (2022)

Exercise interveNtion outdoor proJect in the cOmmunitY – results from the ENJOY program for independence in dementia: a feasibility pilot randomised controlled trial
por: Levinger, Pazit, et al.
Publicado: (2023)

Impact of adherence on subcutaneous interferon beta-1a effectiveness administered by Rebismart(®) in patients with multiple sclerosis
por: Edo Solsona, María Dolores, et al.
Publicado: (2017)

Subcutaneous administration of interferon beta-1a for COVID-19: A non-controlled prospective trial
por: Dastan, Farzaneh, et al.
Publicado: (2020)

Outcomes of COVID-19 among patients treated with subcutaneous interferon beta-1a for multiple sclerosis
por: Freedman, Mark S., et al.
Publicado: (2021)

The ENJOY MAP for HEALTH: Exercise interveNtion outdoor proJect in the cOmmunitY for older people—More Active People for HEALTHier communities: a study protocol
por: Levinger, Pazit, et al.
Publicado: (2022)

Persistence on Therapy and Propensity Matched Outcome Comparison of Two Subcutaneous Interferon Beta 1a Dosages for Multiple Sclerosis
por: Kalincik, Tomas, et al.
Publicado: (2013)

A novel needle for subcutaneous injection of interferon beta-1a: effect on pain in volunteers and satisfaction in patients with multiple sclerosis
por: Jaber, Amer, et al.
Publicado: (2008)

Beta-interferons in multiple sclerosis
por: Aggarwal, Sourabh, et al.
Publicado: (2010)

Immunomodulatory activity of interferon-beta
por: Kasper, Lloyd H, et al.
Publicado: (2014)

Interferons Alpha, Beta, and Omega
por: Meager, Anthony
Publicado: (1998)

Oxidized and Aggregated Recombinant Human Interferon Beta is Immunogenic in Human Interferon Beta Transgenic Mice
por: van Beers, Miranda M. C., et al.
Publicado: (2011)

Severe Subcutaneous Calcification in an Interferon-β-treated MS Patient
por: Masuda, Hiroki, et al.
Publicado: (2017)

Patient-rated suitability of a novel electronic device for self-injection of subcutaneous interferon beta-1a in relapsing multiple sclerosis: an international, single-arm, multicentre, Phase IIIb study
por: Devonshire, Virginia, et al.
Publicado: (2010)

An observational, retrospective, UK and Ireland audit of patient adherence to subcutaneous interferon beta-1a injections using the RebiSmart(®) injection device
por: Willis, Helen, et al.
Publicado: (2014)

Multiple human beta interferon genes
Publicado: (1982)

Shared and Unique Features of Human Interferon-Beta and Interferon-Alpha Subtypes
por: Wittling, Megen C., et al.
Publicado: (2021)

Interferon-gamma-induced local leukocytoclastic vasculitis at the subcutaneous injection site
por: Wang, Fang, et al.
Publicado: (2016)

Evolution of the RebiSmart(®) Electromechanical Autoinjector to Improve Usability in Support of Adherence to Subcutaneous Interferon Beta-1a Therapy for People Living with Multiple Sclerosis
por: Lin, Yu-Ting, et al.
Publicado: (2023)

Synergistic inhibition of human cytomegalovirus replication by interferon-alpha/beta and interferon-gamma
por: Sainz, Bruno, et al.
Publicado: (2005)

Immunotherapy With Interferon α11, But Not Interferon Beta, Controls Persistent Retroviral Infection
por: Schwerdtfeger, Mara, et al.
Publicado: (2022)

Inhibition of suppressor T lymphocytes by murine interferon beta
Publicado: (1987)

Thrombotic microangiopathy associated with use of interferon-beta
por: Olea, Teresa, et al.
Publicado: (2012)

Interferon beta-1a–induced morphea
por: Bezalel, Spencer A., et al.
Publicado: (2014)

Interferon beta-1b for COVID-19
por: Shalhoub, Sarah
Publicado: (2020)

Fenomenología del chisme
por: Castillo Farreras, José
Publicado: (2003)

Las costumbres y el derecho
por: Castillo Farreras, José
Publicado: (1973)

Agonist and antagonist effects of interferon alpha and beta on activation of human macrophages. Two classes of interferon gamma receptors and blockade of the high-affinity sites by interferon alpha or beta
Publicado: (1988)

RARE-28. The use of subcutaneous interferon in patients with craniopharyngioma: an institutional retrospective review
por: Patil, Prabhumallikarjun, et al.
Publicado: (2022)

The Impact of Vascular Disease Treatment on Platelet-Derived Microvesicles
por: Rosińska, Justyna, et al.
Publicado: (2017)

Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: Current Insights into the Disease Pathophysiology, Diagnosis and Management
por: Ambrosius, Wojciech, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_p9sj5ksvo41rqab16n8a018e0q